Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: positive trends in gross margins, reduced interest expenses, and improved cash flow are offset by challenges such as international stent graft sales and AMDS starter set barriers. The Q&A highlights cautious guidance due to geopolitical and supply chain issues. While the company is optimistic about future product launches, current uncertainties and management's reluctance to provide detailed guidance suggest a neutral market reaction. Given the small market cap, any positive or negative developments could lead to more pronounced stock movements.
Key Financial Performance
Total Revenues $116.3 million for Q1 2026, up 12% compared to Q1 2025. Growth driven by On-X and stent grafts, including AMDS, and normalization of tissue processing volumes post-2024 cybersecurity event.
Adjusted EBITDA $22.1 million in Q1 2026, up 26% from $17.5 million in Q1 2025. Improvement driven by leverage in SG&A and gross margin improvement.
Adjusted EBITDA Margin 19% in Q1 2026, an approximate 130 basis point improvement over the prior year, driven by leverage in SG&A and gross margin improvement.
Stent Graft Revenues Increased 10% on a constant currency basis in Q1 2026 compared to Q1 2025. Growth impacted by lower-than-expected AMDS set sales in the U.S. and softer international performance, particularly in the Middle East.
On-X Revenues Grew 17% year-over-year on a constant currency basis in Q1 2026. Growth driven by global market share gains and new U.S. market opportunities unlocked by recent clinical data.
Tissue Processing Revenues Increased 23% year-over-year on a constant currency basis in Q1 2026. Growth attributed to normalization of tissue volumes post-2024 cybersecurity event.
BioGlue Revenues Relatively flat on a constant currency basis in Q1 2026 compared to Q1 2025. Performance slightly lower than mid-single-digit growth expectations due to stocking distributor business variability.
Regional Revenues Asia Pacific increased 6%, North America 23%, EMEA increased 5%, and Latin America decreased 23% in Q1 2026 compared to Q1 2025. International growth impacted by stent graft-related factors and distributor ordering patterns.
Gross Margins 64.9% in Q1 2026, up from 64.2% in Q1 2025. Improvement due to favorable product and geographic mix.
General and Administrative and Marketing Expenses $60.8 million in Q1 2026 compared to $54.7 million in Q1 2025. Non-GAAP expenses were $59.3 million or 51% of sales in Q1 2026, reflecting a 260 basis point improvement due to leveraging infrastructure and reduced launch costs.
R&D Expenses $8.8 million or 7.6% of sales in Q1 2026 compared to $6.7 million or 6.8% of sales in Q1 2025. Increase attributed to ongoing development efforts.
Interest Expense $5.2 million in Q1 2026 compared to $7.5 million in Q1 2025. Decrease due to lower debt levels.
Free Cash Flow Negative $6.8 million in Q1 2026 compared to negative $20.6 million in Q1 2025. Improvement attributed to better cash flow management.
Cash and Debt $55.8 million in cash and $215.4 million in debt as of March 31, 2026. Net leverage ratio reduced to 1.8 from 4.0 in the prior year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NEXUS Aortic Arch Stent Grafts system: Received PMA approval for chronic aortic dissections. It is a minimally invasive treatment for Aortic Arch disease, with compelling clinical data showing high survival and freedom from complications. The U.S. market opportunity is estimated at $150 million annually. Full U.S. commercial launch expected in January 2027.
On-X heart valve: Achieved 17% year-over-year growth driven by global market share gains and new data showing improved outcomes for younger patients. Positioned as the best aortic valve for patients under 65 years.
ARTIZEN IDE trial: Progressing with 26 patients enrolled in a trial for the Arcevo LSA product, targeting aortic dissection and aneurysm. FDA approval expected in 2029, unlocking an $80 million annual U.S. market opportunity.
Market expansion for stent grafts: Plans to bring stent graft products generating revenue in Europe to the U.S. and Japan, aiming to expand the total addressable market.
On-X market opportunity: New $100 million U.S. market opportunity unlocked by data showing benefits of mechanical valves for younger patients.
Revenue growth: Achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth year-over-year in Q1 2026.
Operational efficiencies: Improved adjusted EBITDA margin by 130 basis points to 19% in Q1 2026, driven by leverage in SG&A and gross margin improvement.
Endospan acquisition: Exercised option to acquire Endospan, completing a market-leading Aortic Arch portfolio. Acquisition expected to close in Q2 2026, with financing already in place.
Long-term growth strategy: Focused on a comprehensive product portfolio, market expansion, and pipeline development to drive sustainable growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth: Year-over-year constant currency growth fell below expectations due to lower-than-expected AMDS set sales in the U.S. and softer-than-expected performance internationally, particularly in the Middle East.
International Market Performance: Underperformance in EMEA, APAC, and Latin America due to stent graft-related factors and quarterly fluctuations in distributor ordering patterns, which may impact revenue normalization.
Cybersecurity Incident: Residual effects from the 2024 cybersecurity event continue to influence tissue processing volumes and revenue comparisons.
Acquisition of Endospan: The acquisition involves significant upfront costs ($135 million) and additional expenses ($8 million in 2026), with no meaningful revenue contribution expected until 2027, potentially impacting short-term financials.
AMDS Sales: Initial stocking sales in the U.S. fell short of expectations, and some accounts have deferred purchases pending PMA approval, delaying revenue realization.
BioGlue Revenue: Performance was slightly lower than expected, attributed to variability in stocking distributor business.
Debt and Interest Expense: The company drew $150 million under its term loan facility to fund the Endospan acquisition, increasing quarterly interest expenses to approximately $8 million starting Q3 2026.
R&D and Clinical Expenses: Ongoing R&D and clinical expenses for Endospan and other pipeline projects may strain financial resources in the short term.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Adjusted constant currency growth is expected to be between 7% to 11%, representing a reported revenue range of $480 million to $496 million. This includes a 1 percentage point tailwind from FX.
Adjusted EBITDA Guidance for 2026: Expected to be in the range of $100 million to $107 million, representing 12% to 20% growth over 2025, with approximately 100 basis points of adjusted EBITDA margin expansion at the midpoint.
Impact of Endospan Acquisition on 2026 EBITDA: If the acquisition closes as anticipated, incremental expenses of approximately $8 million are expected, reducing full-year 2026 adjusted EBITDA to $92 million to $99 million.
NEXUS U.S. Commercial Launch: Full U.S. commercial launch of NEXUS is anticipated in January 2027, following efforts to scale inventory production, complete value analysis committee processes, and augment the U.S. sales team.
AMDS PMA Approval: PMA approval of AMDS is anticipated in mid-2026, which will eliminate the need for new accounts to go through the IRB process, potentially accelerating adoption.
ARTIZEN IDE Trial Timeline: Full enrollment of the ARTIZEN clinical trial is anticipated by mid-2027, with FDA approval expected in 2029, unlocking an incremental $80 million annual U.S. market opportunity.
On-X Heart Valve Market Opportunity: Continued global market share gains are expected, driven by clinical data showing benefits for patients under 65 years of age, translating into greater market share globally.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is contemplated in the guidance reset, and what are the expectations for AMDS PMA approval and its impact on revenue?
A:The guidance reset considers trends such as international stents being off due to Middle East issues and supply chain challenges, and AMDS starter set sales being below expectations. PMA approval is expected midyear and is anticipated to help with hospital IRBs and starter set barriers. The guidance is considered prudent given current trends.
Q:What are the next steps for building out the commercial infrastructure for NEXUS?
A:The company plans to go through value analysis committees (4-6 months), build inventory, and hire dedicated clinical specialists. The initial target is 100 high-volume accounts, which can be covered with a small team. Hiring of reps has already started, and the goal is to be ready for a January 1 launch.
Q:What is the status of reordering versus new accounts for AMDS?
A:Reordering from existing accounts has been strong and ahead of expectations. However, there are barriers to new accounts purchasing the $100,000 starter sets, including IRB requirements and financial considerations. Programs are being developed to address these barriers.
Q:What is the growth trajectory and cost offset expectations for NEXUS?
A:NEXUS is expected to address unmet needs for vascular surgeons and drive growth. The company aims to be ready for a January 1 launch. The $8 million incremental cost for 2027 includes launch-related expenses, R&D, and sales force costs, which are expected to be offset by NEXUS revenue, making it EBITDA neutral.
Q:What are the challenges with AMDS starter sets and the company's strategy to address them?
A:Challenges include the $100,000 upfront cost and IRB requirements. The company is not moving to consignment but is developing programs to address these barriers. PMA approval is expected to eliminate the IRB requirement and help with adoption.
Q:What is the status of international stent graft sales and their impact on guidance?
A:International stent graft sales were below expectations due to Middle East issues and supply chain challenges. These factors contributed to the guidance reduction, with half attributed to AMDS set sales and half to international stent grafts.
Q:What are the plans for NEXUS manufacturing and regulatory steps for Duo and Tre in the U.S.?
A:NEXUS manufacturing is scaled for Europe but needs expansion and inventory build-up for the U.S. launch. Duo and Tre will require a clinical trial and FDA approval, with plans for an off-the-shelf version instead of custom-made products.
Q:What are the trends in AMDS reordering behavior?
A:Reordering has been strong, driven by multiple surgeons at larger accounts adopting the technology. Training more surgeons within accounts is spreading usage, contributing to higher reorder rates.
Q:What is the company's approach to cross-selling opportunities with On-X and other products?
A:The company is leveraging its relationships with cardiac and vascular surgeons to cross-sell products like On-X, AMDS, and NEXUS. Training programs and investigator meetings are used to promote the complementary product portfolio.
Q:What are the supply chain challenges and their impact on the portfolio?
A:Supply chain challenges are specific to a small number of products and are being addressed. The issue has been ring-fenced, and solutions are being executed, with the impact factored into the guidance.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the exact number of accounts deferring AMDS for PMA approval and the specific targeted number of accounts for AMDS. They also did not provide detailed breakdowns of U.S. AMDS revenue versus international stent grafts or the exact growth of the core stent business excluding AMDS.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMDS sale
America EMEA
Aortic Arch
Arch portfolio
BioGlue
COO CFO
Endospan RD
Endospan acquisition
Lance detail
Middle East
NEXUS Aortic
NEXUS sale
acquisition Endospan
aneurysm
cohort
committee
comp preservation
contribution
course
currency expectation
dissection
distributor
endoleaks
graft factor
interest expense
pattern
perspective stent
point improvement
preservation service
result expectation
stocking
system
term adoption
timing
trial patient
underperformance
volume cybersecurity
AORT Transcript
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Unknown5-10
The earnings call summary presents a mixed picture: positive trends in gross margins, reduced interest expenses, and improved cash flow are offset by challenges such as international stent graft sales and AMDS starter set barriers. The Q&A highlights cautious guidance due to geopolitical and supply chain issues. While the company is optimistic about future product launches, current uncertainties and management's reluctance to provide detailed guidance suggest a neutral market reaction. Given the small market cap, any positive or negative developments could lead to more pronounced stock movements.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call reveals strong financial performance, optimistic guidance, and strategic product development, especially with AMDS and NEXUS. The Q&A section highlights management's confidence in market opportunities and competitive positioning. Despite some unclear responses, the overall tone is positive. With a market cap of ~$1 billion, the stock is likely to see a positive reaction, in the 2% to 8% range, over the next two weeks.
Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript
Positive11-6
The company shows strong growth across product lines, increased revenue guidance, and improved EBITDA margins. The Q&A reveals excitement around On-X's unique clinical data and AMDS's strong demand. Although management avoided specific 2026 guidance, the positive outlook for product launches and market expansions supports a positive sentiment. With a market cap of approximately $1 billion, the stock is likely to react positively, with a predicted movement of 2% to 8%.
Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-10
AORT Slides
AORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
